This part of an RMP provides a synopsis of a medicinal product’s safety. It should be a summary of:
- The important identified risks
- Important potential risks
- Missing information
It should also address:
- Populations potentially at risk (where the product is likely to be used in labelled and off-labelled use)
- Safety questions which warrant further investigation during the post-authorization period
